The 10-second takeaway
For the quarter ended March 31 (Q1), Cynosure beat expectations on both revenue and earnings per share.
Compared to the prior-year quarter, both revenue and GAAP earnings per share increased. The profit was a surprise, as analysts had predicted a loss.
Margins expanded across the board.
Cynosure logged revenue of $34.2 million. The three analysts polled by S&P Capital IQ wanted to see sales of $31.7 million on the same basis. GAAP-reported sales were 56% higher than the prior-year quarter's $21.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.06. The four earnings estimates compiled by S&P Capital IQ averaged -$0.02 per share. GAAP EPS were $0.06 for Q1 against -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 57.1%, 100 basis points better than the prior-year quarter. Operating margin was 2.5%, 1,010 basis points better than the prior-year quarter. Net margin was 2.4%, 1,110 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $35.8 million. On the bottom line, the average EPS estimate is $0.08.
Next year's average estimate for revenue is $137.6 million. The average EPS estimate is $0.30.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 368 members rating the stock outperform and 13 members rating it underperform. Among 93 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 88 give Cynosure a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is buy, with an average price target of $22.20.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Cynosure performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Cynosure to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Cynosure, RetailMeNot, and TransUnion Jumped Today
Another record day for the market featured these rising stocks. Find out why.
Here's Why Cynosure, Inc. is Soaring Today
Shares skyrocket after the company accepts a buyout offer from Hologic.
Why Cynosure, Inc. Is Rising Today
Rumors that the company could be an acquisition target caused shares to spike on Monday.